BlackRock’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

BlackRock’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-825,810	Closed	-$2.18M	–	5226
2020 Q1	$2.18M	Sell	825,810 -28,309	-3%	-$46.4K	﹤0.01%	3630
2019 Q4	$1.01M	Sell	854,119 -50,071	-6%	-$80K	﹤0.01%	3995
2019 Q3	$1.56M	Buy	904,190 +138,340	+18%	+$421K	﹤0.01%	3830
2019 Q2	$3.63M	Buy	765,850 +79,729	+12%	+$446K	﹤0.01%	3611
2019 Q1	$4.43M	Buy	686,121 +378,339	+123%	+$1.98M	﹤0.01%	3454
2018 Q4	$1.55M	Buy	307,782 +32,943	+12%	+$231K	﹤0.01%	3756
2018 Q3	$2.35M	Buy	+274,839	New	+$3.05M	﹤0.01%	3719

BlackRock's NTGN Position: Q2 2020 in Review

BlackRock sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 825,810 shares — an estimated $2.18M sold.

BlackRock first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $4.43M in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

BlackRock reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
BlackRock sold 825,810 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $2.18M.
BlackRock first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
BlackRock's Neon Therapeutics, Inc. Common Stock position peaked at $4.43M in Q1 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on BlackRock's 13F filing for Q2 2020, filed 14 Aug 2020.